Tina Liu
|
Partner, Tompkins Wake
Tina Liu is a partner at Tompkins Wake and leads the firm’s life sciences, health-tech and biotechnology practice. Her work spans the regulatory, commercial and strategic landscape of New Zealand’s health-tech and therapeutic product sectors. Tina advises major health-tech and bio-pharma companies, biotech ventures, clinical research organisations, and product developers on the full lifecycle of therapeutic and tech products—from classification and pre-market approval, through to distribution, advertising, licensing, and post-market obligations.
Tina has particular expertise negotiating and advising on listing and subsidy arrangements with PHARMAC, and providing New Zealand legal support for global pharmaceutical recalls. Tina co-authored the New Zealand chapter of Pharmaceutical Advertising for The Legal 500’s 2024/2025 global guide and regularly contributes to international legal publications including Chambers and Partners Global Practice Guides. |
|
AI in Clinical Decision-Making: The Case for Cautious Optimism
As AI begins to influence clinical research, its application in clinical decision making raises ethical, legal and governance challenges, particularly around informed consent, data protection and sponsor liability.
The USA, EU, UK and Australia are responding to these challenges with new laws, voluntary standards and regulatory guidance.
New Zealand does not have legislation governing the use of AI in any sector. However, New Zealand’s clinical research industry now has the opportunity, drawing on global developments, to establish guardrails for balancing clinical innovation with the legal and ethical use of AI.
This session will:
AI is here. We need to embrace it, but with cautious optimism.
The USA, EU, UK and Australia are responding to these challenges with new laws, voluntary standards and regulatory guidance.
New Zealand does not have legislation governing the use of AI in any sector. However, New Zealand’s clinical research industry now has the opportunity, drawing on global developments, to establish guardrails for balancing clinical innovation with the legal and ethical use of AI.
This session will:
- identify and discuss the key risks posed by AI when used in clinical decision-making including implications for obtaining informed consent, data security vulnerabilities, and the complexity of assigning liability when third party AI systems are involved
- provide a practical framework for clinical researchers and organisations to help develop guardrails for using AI, drawing from international developments
AI is here. We need to embrace it, but with cautious optimism.
